Users Coming Off Slimming Medications Gain Back Weight Far More Rapidly Compared to Those on Conventional Diets

Fresh analysis indicates that individuals who come off new slimming jabs like Mounjaro or Wegovy can put back on lost weight far faster than those who end traditional lifestyle plans.

Research printed in a leading health publication points out that while obese people often shed a large proportion of their body weight while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month after stopping.

"People purchasing such drugs should be aware of the potential of rapid rebound weight gain when the medication concludes," cautioned researcher Dr. Susan Jebb.

That rate of recovery suggests a reversion to original mass within about one and a half years.

Comparing Treatments

The study, which reviewed dozens of trials involving over 9,000 of participants, contrasted the outcomes of the injectable medications with other pills.

The team note that people who lose weight through diet and exercise usually experience a less rapid creep back—around 0.1 kg a month—post-intervention.

Understanding the Rapid Regain

Experts believe the mechanism of the drugs accounts for the amplified rebound.

GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which controls hunger.

"Sustained high doses of GLP-1 concentrations far above than normal might result in the system to produce less of its own natural hormone, and could reduce sensitivity to its effects," said Dr. Adam Collins, a dietetics specialist.

"Withdrawal of this GLP-1 'fix' results in appetite is no longer kept in check, making excessive eating much more probable."

An Ongoing Disease?

The NHS suggest the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.

Many experts say that, considering the significant potential of weight regain, the treatment should be considered long-term.

This view is echoed by pharmaceutical companies, who note that the results "highlight the long-term nature of obesity," akin to managing diseases like hypertension.

Patient Accounts

People who have come off the jabs describe a sudden resurgence of cravings.

"It was like something activating and I was suddenly ravenous," recalled an individual.

This difficulty is exacerbated if individuals have not established sustainable lifestyle or habit changes during therapy.

Significant Interest

Survey data suggest that a significant number of people in the UK have tried these injections in the last 12 months, with demand being substantial.

• Use is more common among women than men.
• The 40s and 50s demographic shows the highest level of interest.
• Many obtain the drugs through private prescriptions rather than the NHS.

Finally, experts caution that while GLP-1 drugs are potent tools for weight loss, they are not a standalone fix and lasting health benefits relies on integrated behavioural support.